Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 12;13(8):1439.
doi: 10.3390/genes13081439.

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

Ayoub Saaid  1 , Matteo Monticelli  2 , Alessia Andrea Ricci  3 , Giulia Orlando  4 , Cristina Botta  3 , Pietro Zeppa  1 , Andrea Bianconi  1 , Simona Osella-Abate  3 , Francesco Bruno  5 , Alessia Pellerino  5 , Roberta Rudà  5   6 , Paola Cassoni  3 , Diego Garbossa  1 , Fabio Cofano  1 , Luca Bertero  3
Affiliations

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

Ayoub Saaid et al. Genes (Basel). .

Abstract

The G105G SNP (rs11554137) in the IDH1 gene is observed in about 10-15% of patients with a diffuse glioma. Data regarding its impact on gliomas are poor and partially conflicting, possibly due to the evolving classification of CNS tumors. The aim of this study was to investigate the G105G SNP prognostic significance in a homogenous cohort of IDH-wildtype glioblastomas, in agreement with the 2021 WHO classification. The study analyzed 211 patients by collecting several clinico-pathological and molecular characteristics, including the age, lesion localization, number of involved lobes, type of surgical treatment, disease outcome and MGMT promoter methylation status. PFS and DSS curves were plotted according to the Kaplan-Meier method and statistical analyses were performed using parametric and non-parametric tests. A total of 32 patients out of 211 (15.2%) were found to be G105G SNP carriers. No significant impact of the IDH1 G105G SNP on patients' outcomes was observed in terms of PFS and DSS, while MGMT promoter methylation and gross total resection resulted as key prognostic factors in our cohort as expected. No prognostic impact of the IDH1 G105G SNP was detected in this strict cohort of IDH-wildtype glioblastomas. Analysis of larger cohorts is warranted to address the sample size limitations.

Keywords: IDH1; SNP; glioblastoma; prognosis; rs11554137.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PFS according to IDH1 G105G status. No significant difference was detected (p = 0.9770).
Figure 2
Figure 2
DSS according to IDH1 G105G status. No significant difference was detected (p = 0.1833).
See this image and copyright information in PMC

References

    1. Louis D.N., Perry A., Reifenberger G., Von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Dang L., Yen K., Attar E.C. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann. Oncol. 2016;27:599–608. doi: 10.1093/annonc/mdw013. - DOI - PubMed
    1. Issa G.C., DiNardo C.D. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11:107. doi: 10.1038/s41408-021-00497-1. - DOI - PMC - PubMed
    1. Acquaviva G., Visani M., De Biase D., Marucci G., Franceschi E., Tosoni A., Brandes A.A., Rhoden K.J., Pession A., Tallini G. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients. Sci. Rep. 2018;8:4459. doi: 10.1038/s41598-018-22222-y. - DOI - PMC - PubMed

Publication types

Substances